**Supplementary File 2.**

**Table 1. Summary of online tools and materials identified and selected according to the inclusion criteria.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Source** | **Content description** | **Format** | **Year published or delivered** | **Target Audience** | **Access-ibility** | **Assess-ment**  | **Link (if applicable)** |
| **HTA bodies (including REDETS which is a network of Spanish HTA bodies)** |
| 1 | ACE | Explains what HTA is and ACE's processes and methods | Webpage(s) | 2021 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.ace-hta.gov.sg/resources/process-methods#health-technology |
| 2 | ACE | Explains what HTA is and ACE's processes and methods | Short Video | 2021 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=OzGWxYwmkI0 |
| 3 | ACE | Glossary List | PDF document | 2018 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.ace-hta.gov.sg/docs/default-source/default-library/ace-glossary-list-(5-feb-2018).PDF document?sfvrsn=2b3e3400\_0 |
| 4 | CADTH | Explains patient and community engagement, participation methods, PI in their organizational government, common acronyms | Webpage(s) | 2019 | Patients, families, communities, patient groups | Free, 24/24 | No | https://www.cadth.ca/patient-and-community-engagement |
| 5 | CADTH | Covering a variety of topics including HTA, process and methods, patient engagement, patient perspectives etc. | Online symposium | 2021 | Public (professionals and patients and citizens) | Fee, subscription required | No | Program: https://canjhealthtechnol.ca/index.php/cjht/issue/view/13/symp2021 |
| 6 | CADTH | Explains the process of CADTH Drug Reimbursement Reviews | Short Video | 2021 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=TqC8f44nny4 |
| 7 | CDE | Explains the decision-making process for medicines reimbursement under the national health insurance and role of CDE and other actors | Short Video | 2017 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=p\_Jf\_\_eDFPM |
| 8 | G-BA | Covers HTA, methods and governance, coordination meetings (e.g., EU HTA) | Online modules  | Ongoing | Patient representatives | Fee, subscription required | No | NA |
| 9 | G-BA | Soft skills training including presentation, speaking, virtual meeting communications  | Online modules | Ongoing | Patient representatives | Fee, subscription required | No | NA |
| 10 | HAS | Guidelines on how to contribute to a patient submission for a medicine assessment (reimbursement and early access), patient submission template | Online webpage | Ongoing | Patients, Patient organizations | Free, 24/24 | No | https://www.has-sante.fr/jcms/p\_3114053/fr/contribution-des-associations-de-patients-et-d-usagers-aux-evaluations-de-medicaments |
| 11 | HAS | Guidelines on how to submit a patient organization submission for a medical device, patient organization submission template | Online webpage | Ongoing | Patients, Consumers, Patient organizations | Free, 24/24 | No | https://www.has-sante.fr/jcms/p\_3114057/fr/contribuer-a-l-evaluation-des-dispositifs-medicaux |
| 12 | HAS (+ANSM) | Early access medicines: process and practical arrangements, data collection, consumer participation; role of ANSM and benefit/risk assessment; HAS doctrine and criteria assessment arrangements. | Webinar (Q+A) | 2021 | Public (professionals, and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=6E-35zFrtyk |
| 13 | HAS | Online patient and consumer guide to early access medicines: medicines concerned, access conditions, role of patient and consumer organizations,  | Online webpage | 2021 | Patients, Consumers, Patient organizations | Free, 24/24 | No | https://www.has-sante.fr/jcms/p\_3274374/fr/medicament-en-acces-precoce-ce-qu-il-faut-savoir |
| 14 | HAS | Medicines devices assessment:Information Day for patient organizations covering topics such as HAS and patient organizations, commissions and patient organizations, patient organization submissions | PowerPoint Slides | 2018 | Patients, Consumers, Patient organizations | Free, 24/24 | No | https://www.has-sante.fr/upload/docs/application/PDF document/2018-10/presentation\_journee\_association\_de\_patients.PDF document |
| 15 | HAS | Session 3 – The patient perspective in health technology assessment | Webinar (Q+A) and in-person session | 2016 | Public (professionals, and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=WS00sPnZXFU&t=3551s |
| 16 | HAS | 1st annual webinar of public involvement for patients and consumers: The panorama of user involvement, Health product assessments | Webinar (Q+A) | 2020 | Patients, Consumers, Patient organizations | Free, 24/24 | No | https://www.youtube.com/watch?v=RBF4GHxZJtg&list=PLigcT8O\_Dnsizk0kcaHVt6w3Whc9LKxLq&index=3 |
| 17 | HAS | 2nd annual webinar of public involvement for patients and consumers- Facilitating your arrival to participate in the work of the HAS, Medicines, and health technologies: developments in health technology assessment and focus on early access | Webinar (Q+A) | 2021 | Patients, Consumers, Patient organizations | Free, 24/24 | No | https://www.youtube.com/watch?v=oZu18au4zv4&list=PLigcT8O\_Dnsizk0kcaHVt6w3Whc9LKxLq&index=2 |
| 18 | HITAP | Explains what HTA is, and roles of different stakeholders in the HTA process | Short Video | 2014 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=QnmnyZ14A4w |
| 19 | HIQA | Guide to explain HTA at the HIQA: overview of HTA, HTA process, HTA content, outcomes of assessment, further information including references | PDF document | 2016 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.hiqa.ie/sites/default/files/2017-01/A-Guide-to-Health-Technology-Assessment.PDF document |
| 20 | HIQA | Provides guidelines for evaluating clinical effectiveness for health technologies in Ireland, definitions of key terms, measures of effect, methods of comparison,  | PDF document | 2018 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.hiqa.ie/sites/default/files/2019-01/Clinical-Effectiveness-Guidelines.PDF document |
| 21 | HIQA | Provides an overview of what HTA is, economic guidelines including type of evaluation, cost perspectives, outcome perspectives, choice of comparator, synthesis of effectiveness, outcome measurement, discount rate, sensitivity analysis, equity rating | PDF document | 2020 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.hiqa.ie/sites/default/files/2020-09/HTA-Economic-Guidelines-2020.PDF document |
| 22 | HTA-AU | Explains HTA for Australian Government subsidy, purpose of HTA, public involvement in HTA, | Webpage(s) | 2021 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.health.gov.au/topics/health-technologies-and-digital-health/health-technology-assessments |
| 23 | HTA-AU | Explains the Role of Consumer Engagement and Evidence, consumer HTA experiences  | Online symposium | 2021 | Public (professionals and patients and citizens) | Fee, subscription required | No | https://hta.joyn-us.app/talks?types=36 (link expired) |
| 24 | HTW | Guide to Patient/Carer Group Submissions: includes types of information to be included in the submission, methods to collect this information | PDF document  | 2019 | Patient and carer groups | Free, 24/24 | No | https://www.healthtechnology.wales/wp-content/uploads/2021/03/HTW-Guide-to-Patient-or-Carer-Group-Submissions-English.PDF document |
| 25 | HTW | Attending a Health Technology Wales Appraisal Panel meeting: key replies to questions asked about these appraisal meetings | PDF document  | 2019 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.healthtechnology.wales/wp-content/uploads/2019/10/20191028-Attending-a-HTW-Appraisal-Panel-meeting-factsheet.PDF document |
| 26 | HTW | Explains how Health Technology Wales (HTW) performs 'health technology assessments' to determine the potential value of health interventions and how patient groups can get involved in that process. | Webinar (Q+A) | 2020 | Patient groups | Free, 24/24 | No | https://www.youtube.com/watch?v=bWEELvvgRjQ&t=13s |
| 27 | INESSS | Governance, methods of patient and citizen participation | PowerPoint Slides | 2021 | Patient groups | Free, accessible upon demand | No | NA |
| 28 | IQWIG | Explains how patients can participate and requirements of such participation (report plans, preliminary reports, preliminary ThemenCheck reports, drafts of the General Methods) | Webpage(s) | 2021 | Public including Patients, patient groups | Free, 24/24 | No | https://www.iqwig.de/en/participation/contributing-the-patients-perspective/ |
| 29 | KCE | Explains the different HTA processes, how patients can participate in the KCE's work, levels of engagement, type of patients involved, how they are identified, recruted and selected | PowerPoint Slides | 2021 | Patient groups | Free, accessible upon demand | No | NA |
| 30 | NICE | Provides overview of the different forms of technology appraisal at the NICE, explains NHS constitutions, technology appraisal decisions, guidance overview, more information | Online webpage | 2019 | Public (including professionals, industry and patients and citizens) | Free, 24/24 | No | https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance |
| 31 | NICE | Explains what technology appraisals are, scoping, how patient and carer organizations can get involved in scoping, the scoping consultation, the scoping workshop | PDF document | 2015 | Patient and carer organizations | Free, 24/24 | No | https://www.nice.org.uk/Media/Default/About/NICE-Communities/Public-involvement/Developing-NICE-guidance/Scoping-Technology-Appraisals-Factsheet-Patient-Carer.PDF document |
| 32 | NICE | Explains patient and public involvement in medicines appraisals at NICE, market access and HTA in England, role of committee, patient experts and what they provide | PowerPoint Slides | 2021 | Patient experts (in briefing) | Free, accessible upon demand | No | NA |
| 33 | NICE | Explains public involvement medical technologies guidance, role of committee, levels of evidence in MedTech evaluation | PowerPoint Slides | 2021 | Patient experts (in briefing) | Free, accessible upon demand | No | NA |
| 34 | NICE | Explains NICE Public Involvement Programme, in relation to Types of patient input for medical technology guidance | PowerPoint Slides | 2021 | Lay members, patient experts | Free, accessible upon demand | No | NA |
| 35 | NICE | NICE lay member toolkit- covers who to ask, tips for preparing new role and first meeting, what happens after the meeting, preparing for all committee meetings, role during committee meetings, role in final stages of developing NICE guideline | Word document  | 2021 | Lay members | Free, accessible upon demand | No | NA |
| 36 | NICE | Series of online modules- introduction to NICE, role and value, being an effective lay member, committees, how NICE uses evidence, equalities, introduction to health economics, working with networks | Online internal modules | 2021- ongoing | Patient representatives and consumer groups involved in NICE's work | Free, accessible upon demand | Yes (feedback) | NA |
| 37 | NICE | Covers communication tips during a virtual meeting | PDF document | 2020 | Lay members | Free, accessible upon demand | No | NA |
| 38 | RedETS | Covers: Current framework of HTA in the Spanish national health system, Participation of patients and citizens in HTA, quantitative and qualitative research methods, health research, Practical aspects of patient and citizen participation for an effective HTA contribution  | PDF document | 2020 | Patients, citizens  | Free, accessible upon demand | No | NA |
| 39 | SHTG | Guide to Support Patient Organization Submissions including information required for a submission, how to collect this information | PDF document | 2021 | Patient groups | Free, 24/24 | No | https://shtg.scot/media/1802/guide-to-support-patient-organisation-submissions.PDF document |
| 40 | SMC | Guide for Patient Group Partners- covers the SMC process and planning and completing a submission, useful resources | PDF document | 2017 | Patient groups | Free, 24/24 | No | https://www.scottishmedicines.org.uk/making-a-submission/ |
| 41 | SMC | HTA training- public involvement in HTA, submission form and guide, Patient and Clinical Engagement  | PowerPoint Slides | 2016 | SMC members, Patient groups | Free, 24/24 | No | https://www.slideshare.net/ipposi/hta-training-jennifer-dickson-scottich-medicines-consortium-july-26th-2016 |
| 42 | SMC | Explains how SMC pharmacists assess a medicine- issues with clinical trials, importance of critical appraisal, assessment team. | Short Video | 2018 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=6AnDuZTW\_6c |
| **European and international patient and consumer groups**  |
| 43 | Beacon UK | HTA course including description of the different UK HTA agencies and their respective HTA processes, patient involvement in HTA with the focus on rare diseases, glossary list | MOOC | 2021 | Rare disease advocates, patient groups and charities, | Free, subscription required | Yes | https://portal.findacure.org.uk/index.php? |
| 44 | Beacon UK | Health economics understanding explains what HTA is, preparing patient group for HTA,  | Webinar (Q+A) | 2021 | Rare disease advocates, patient groups and charities, | Free, 24/24 | No | https://www.youtube.com/watch?v=zkdjiO0k1Ew |
| 45 | ECPC | Covers what is HTA, practical guide for patient contribution to HTA, getting involved in the regional/national level, references, glossary | Online Module (toolkit) | 2021 | Representatives of ECPC member organizations, | Free, 24/24 | No | https://ecpc.org/tool-box/health-technology-assessment-e-module/ |
| 46 | ECPC | Understanding Health Technology Assessment covers Health economics, Involvement of Patient Organisations in the HTA Process, value of health, clinical trials, references | PDF | 2019 | Patients | Free, 24/24 | No | https://ecpc.org/wp-content/uploads/2019/08/ECPC-HTA-E-Module-Understanding-Health-Technology-Assessment-a-Guide-for-Patients-2.pdf |
| 47 | EUPATI | Glossary List | Webpage(s) | 2019- | Public including Patients, patient groups, citizens,  | Free, 24/24 | No | https://toolbox.eupati.eu/glossary/ |
| 48 | EUPATI | HTA course: introduction, bodies and principles, quantitative and qualitative evaluation methods, patient involvement in HTA | MOOC | 2012 | Public including Patients, patient groups, citizens,  | Free, subscription required | Yes, for a fee | https://learning.eupati.eu/local/coursecatalogue/index.php?categoryid=7 |
| 49 | EURORDIS | Covers: Recommendations on the required capabilities for patient engagement, conflict of interest in patient engagement, market access and HTA | MOOC | 2015- ongoing | Public including Patients, patient groups, citizens,  | Free, subscription required | Yes  | https://openacademy.eurordis.org/all-courses/ |
| 50 | IAPO | Provides definition of what HTA is, a health technology, policy landmarks including Patients’ unique views can increase the quality ofdecision-making, Patients’ experiences can represent an invaluable sourceof data, What makes patients’ input truly unique? | PDF document | 2017 | Public, including Patients and patient representatives | Free, 24/24 | No | https://www.iapo.org.uk/sites/default/files/files/Policy%20Briefing%204\_2.PDF document |
| 51 | IPPOSI | Principles and practices of Health Technology Assessment (HTA) –what a health technology is, what HTA is, and why it is becoming increasingly important within Europeanhealth systems, how patients can become involved with HTA | Webinar (Q+A) | 2021-ongoing | Patients and patient representatives | Free, subscription required | Yes | https://www.ipposi.ie/our-work/education/2021-patient-education-programme/ |
| 52 | LE | Covers what Health Technology Assessment (HTA) is, why is patient involvement in HTA is important, at what point and how patients can get involved in HTA and what patients can contribute to the process. | Webinar (Q+A) | 2021 | Public, including Patients and patient representatives | Free, 24/24 | No | https://www.youtube.com/watch?v=OIFPltM1KLQ |
| 53 | MPE | Covers what HTA is, when does it take place, who conducts, information assessed, appraisal committees, criteria for HTA bodies in decision-making, how patient organizations can influence HTA decisions, references | Online webpage | 2017 | Public, including Patients and patient representatives | Free, 24/24 | No | https://www.mpeurope.org/what-we-do/publications/qas/health-technology-assessment-hta/ |
| 54 | MPE | Webinar on reimbursement and Health Technology Assessment (HTA) in Europe covering HTAi standards and values, why HTA needs patient involvement, patient input, examples of evidence, ethics, | Webinar (Q+A) | 2020 | Patients and patient representatives | Free, 24/24 | No | https://www.youtube.com/watch?v=LG26T9wbcSA |
| 55 | PVI | Covers what patient-based evidence is, Patient preference research: what it is, how is it used, PROMS research, qualitative research in HTA | Webinar (Q+A) | 2020 | Public, including Patients and patient groups | Free, 24/24 | No | https://www.youtube.com/watch?v=VaBGCr4YaL0&t=2875s |
| 56 | PVI | Explains how Australia's healthcare reimbursement system works and how patients and patient groups can get involved  | Short Video | 2020 | Public, including Patients and patient groups | Free, 24/24 | No | https://www.youtube.com/watch?v=pO7hJLn3V7k |
| 57 | PVI | Patient based evidence for PBAC and MSAC submissions covers why patient groups might want to get involved in research into patients' needs, preferences and experiences. | Short Video | 2020 | Public, including Patients and patient groups | Free, 24/24 | No | https://www.youtube.com/watch?v=vkAW\_2mxR3o&t=1s |
| 58 | PVI | The patient voice and health economics, role of patient and consumer groups, how consumer input is taken into consideration | Short Video | 2021 | Public, including Patients and patient groups | Free, 24/24 | No | https://www.youtube.com/watch?v=DthUDqp08u4&t=2169s |
| **Other bodies** |
| 59 | ANSM | Consumer guide to the ANSM: missions, values, medicines cycle and procedures, medical device cycle and procedures, patient input in pharmacovigilance | PDF document | 2021 | Public, including Patients and patient groups | Free, 24/24 | No | https://ansm.sante.fr/uploads/2021/09/15/livret-usager-ansm-v5.PDF document |
| 60 | ANSES | Biotechnologies: Risk assessment, technology assessment and responsible research and innovation, public engagement | Webinar (no Q+A) | 2021 | Public (professionals and patients and citizens) | Free, 24/24 | No | https://www.youtube.com/watch?v=a7xLZ5CNWUg |
| 61 | EMA | Principles of HTA, evidence for HTA, example of NICE health technology appraisal | Short Video | 2013 | Public, including Patients and patient groups and other stakeholders | Free, 24/24 | No | https://www.youtube.com/watch?v=bz\_QjA71pAU |
| 62 | EUnetHTA | Explains the patient and social aspect domain which takes patients or individuals in whose care a healthtechnology is used as a point of reference in an HTA, why it is important, relation to other domains in the Core Model, screening and pharmaceutical specific content | PDF document | 2016 | Public (including professionals, industry and patients and citizens) | Free, 24/24 | No | https://www.eunethta.eu/wp-content/uploads/2018/03/HTACoreModel3.0-1.PDF document |
| 63 | EUnetHTA | Patient Input in Relative Effectiveness Assessments, definitions of patients and caregivers, patient input, confidentiality, methods for patient input | PDF document | 2019 | Patients and consumers | Free, 24/24 | No | https://www.eunethta.eu/wp-content/uploads/2019/06/Final\_290519\_Patient-Input-in-REAs.PDF document |
| 64 | GIN | Delivers on tools and tips on how to support patient involvement in HTA- differences between patient input and patient evidence, highlights the international values and standards for HTAs, the lifecycle of patient input into HTAs and considering impact of this input, includes references | Webpage(s)  | 2020 | Public, including Patients and patient representatives | Free, 24/24 | No | https://g-i-n.net/chapter/patient-involvement-in-hta |
| 65 | HTAi | Patient involvement in HTA, first book- demonstrates academic, policy, HTA practice and patient organization perspectives that are focused on HTADetails the policy foundation, case studies of current experience and methods to obtain patients' perspectives  | E-book (as well as softcover or hardcover book)  | 2017 | Public including academics, professionals and patients and citizens | Fee, purchase required | No | https://link.springer.com/book/10.1007/978-981-10-4068-9 |
| 66 | HTAi | Explains what early HTA is in a simplified, animated format | Short Video | 2021 | Public including professionals and patients and citizens | Free, 24/24 | No | https://www.youtube.com/watch?v=FFD3ONj5h5I |
| 67 | HTAi | Introduction to Health Technology Assessment (HTA)- health care systems, what it is, how can patients can patients get involved, who will help patients get involved | PowerPoint Slides | 2018 | Patients and citizens | Free, 24/24 | No | https://past.htai.org/wp-content/uploads/2018/02/PCISG-Resource-Intro\_to\_HTA\_\_KFacey\_\_Jun13.pdf?\_ga=2.205262864.1215750554.1680250774-499806227.1674116182&\_gl=1\*z5624p\*\_ga\*NDk5ODA2MjI3LjE2NzQxMTYxODI.\*\_ga\_79CPBECN0V\*MTY4MDI1MDc3My4xMy4wLjE2ODAyNTA3NzMuMC4wLjA. |
| 68 | HTAi | Provides an overview of the HTA process and how the submission will be used in the assessment of the medicine and to make recommendations, steps involved in completing a submission, methods to collect patient and caregiver input, summarizing and reporting responses | PDF document | 2014 | Patient organizations | Free, 24/24 | No | https://past.htai.org/wp-content/uploads/2018/02/PCISG-Resource-GuidanceandChecklist-Dec14.PDF document?\_ga=2.249323076.2131196868.1676746373-499806227.1674116182&\_gl=1\*1lsbt0u\*\_ga\*NDk5ODA2MjI3LjE2NzQxMTYxODI.\*\_ga\_79CPBECN0V\*MTY3Njc0NjM3Mi44LjEuMTY3Njc0NjM3OS4wLjAuMA.. |
| 69 | HTAi | Provides guidance for patient organizations on the Summary of Information for Patients template explaining the 4 sections: submission summary, current landscape, the medicine, further information, glossary, and references  | Word document  | 2021 | Patient organizations | Free, 24/24 | No | https://past.htai.org/wp-content/uploads/2021/09/02\_Guidance-for-Patient-Organisations-When-Using-the-SIP.docx |
| 70 | HTAi | Ethical considerations for patient groups collecting and reporting information for HTA submissions | PDF document | 2016 | Patient organizations | Free, 24/24 | No | https://past.htai.org/wp-content/uploads/2018/02/PCISG-Resource-EthicsShortGuide\_May16.pdf |
| 71 | HTAi | Good Practice Examples of Patient and Public Involvementin Health Technology Assessment - contains examples of the way in which HTA agencies involve patients and the public inHTA. | PDF document | 2015 | Public including Patient organizations | Free, 24/24 | No | https://past.htai.org/wp-content/uploads/2018/02/Good\_Practice\_Examples\_Feb\_2015.pdf |
| 72 | HTAi | Provides the values and quality standards for patient involvement in HTA including the general and individual HTA processes | PDF document | 2014 | Public including Patient organizations | Free, 24/24 | No | https://past.htai.org/wp-content/uploads/2018/02/PCISG-Info-ValuesandStandards-30-Jun14.PDF document?\_ga=2.36231330.327388941.1676883027-499806227.1674116182&\_gl=1\*jfvy9u\*\_ga\*NDk5ODA2MjI3LjE2NzQxMTYxODI.\*\_ga\_79CPBECN0V\*MTY3Njg4NjY2OC4xMC4xLjE2NzY4ODc1NDguMC4wLjA. |
| 73 | HTAi | HTAi Glossary | Webpage(s) | Ongoing | Public including patients and patient organizations | Free, 24/24 | No | http://htaglossary.net/HomePage |
| 74 | HTAi | HTAi Patient Preferences Webinar Series: understand the role of patient preferences in HTA reviews, Designing Patient Preference Studies for HTA, Patient Preferences Research in HTA Decision-Making, Patient Preferences and Values Studies in Oncology and Rare Diseases | Webinar (Q+A) | 2020 | Public including patients and patient organizations | Free, 24/24 | No | https://htai.org/patient-and-citizen-involvement/ |
| 75 | HTAi | Presentation of the assessment of the current landscape of HTA use of patient preferences in HTA decision-making, including role of PPI in HTA | Webinar (Q+A) (including panel) | 2021 | Public including patients and patient organizations | Free, 24/24 | No | https://www.youtube.com/watch?v=W\_wvo86Pek8 |
| 76 | INAHTA | Presentation of patient involvement experiences of two HTA agencies who have used the PCIG resources  | Webinar (Q+A) | 2017 | Public including patients and patient organizations | Free, 24/24 | No | https://www.dropbox.com/s/r6ieika37813w68/INAHTA%20Patient%20Involvement%20Webinar\_2017.mp4?dl=0%C2%A0 |
| 77 | INAHTA | Position statement on patient involvement- who, what, when, why, references  | PDF document | 2021 | Public including patients and patient organizations | Free, 24/24 | No | https://www.inahta.org/download/inahta-position-statement-on-patient-involvement/?wpdmdl=9586 |
| 78 | ISPOR | HTA training program, introduction to HTA- covers what is HTA, why is it important, what are the best practices, current and future issues, implementing HTA, local considerations, framing and scoping in HTA | Online internal modules | 2021 | Public- Ministries of Health, HTA bodies, public and private payers, industry, health plans, academia, and patient group representatives | Fee, subscription required | Yes | https://www.ispor.org/conferences-education/education-training/hta-training-program |
| 79 | NIHR | Covers knowledge of the NIHR and Patient and Public Involvement (PPI), public reviewing roles and useful skills, how to review research documents from a patient and public point of view | MOOC | 2018 | New and experienced patient/public reviewers of health and social care research | Free, 24/24 | No | https://www.learningforinvolvement.org.uk/an-interactive-course-for-new-and-experienced-patient-public-reviewers-of-health-and-social-care-research/ |
| 80 | NLM-NICHSR  | Origins of technology assessment, early health technology assessment, fundamental concepts, and definitions, basic HTA frameworks, references, glossary  | Webpage(s) | 2019 | Public including professionals and patients and citizens | Free, 24/24 | No | https://www.nlm.nih.gov/nichsr/hta101/ta10103.html |
| 81 | PARADIGM | Early dialogues in HTA: rationale for engaging patients in Early Dialogues | Word document, PDF document (toolkit)  | 2020 | HTA bodies, Patients  | Free, 24/24 | No | https://imi-paradigm.eu/petoolbox/pe-in-ed-hta/ |
| 82 | WHO  | Provides key definition of HTA, references | Webpage(s) | ? (Ongoing) | Public including professionals and patients and citizens | Free, 24/24 | No | https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/assessment |

**Table 2. Selected training tools classified according to key HTA themes.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Source** | **Content description** | **1. What is HTA** | **2.What is the HTA procedure of a medicine, medical device, professional practice?** | **3.Definition and explanation of clinical-effectiveness assessments and/or economic assessments** | **4.Methods of information collection for HTA and the type of information required to conduct HTA?** | **5. Definition and explanation of the outcomes of HTA** |
| **HTA bodies (including REDETS which is a network of Spanish HTA bodies)** |
| 1 | ACE | Explains what HTA is and ACE's processes and methods | x | x | x | x | x |
| 2 | ACE | Explains what HTA is and ACE's processes and methods | x | x | x | x | x |
| 3 | ACE | Glossary List | x |  |  |  |  |
| 4 | CADTH | Explains patient and community engagement, participation methods, PI in their organizational government, common acronyms |  |  |  | x | x |
| 5 | CADTH | Covering a variety of topics including HTA, process and methods, patient engagement, patient perspectives etc. | x | x | x |  | x |
| 6 | CADTH | Explains the process of CADTH Drug Reimbursement Reviews |  | x |  | x | x |
| 7 | CDE | Explains the decision-making process for medicines reimbursement under the national health insurance and role of CDE and other actors | x | x |  | x | x |
| 8 | G-BA | Covers HTA, methods and governance, coordination meetings (e.g., EU HTA) | x | x | x | x | x |
| 9 | G-BA | Soft skills training including presentation, speaking, virtual meeting communications |  |  |  |  |  |
| 10 | HAS | Guidelines on how to contribute to a patient submission for a medicine assessment (reimbursement and early access), patient submission template |  | x |  |  |  |
| 11 | HAS | Guidelines on how to submit a patient organization submission for a medical device, patient organization submission template |  | x |  |  |  |
| 12 | HAS (+ANSM) | Early access medicines: process and practical arrangements, data collection, consumer participation; role of ANSM and benefit/risk assessment; HAS doctrine and criteria assessment arrangements. |  | x |  | x | x |
| 13 | HAS | Online patient and consumer guide to early access medicines: medicines concerned, access conditions, role of patient and consumer organizations, |  | x |  | x | x |
| 14 | HAS | Medicines devices assessment:Information Day for patient organizations covering topics such as HAS and patient organizations, commissions and patient organizations, patient organization submissions |  | x | x | x | x |
| 15 | HAS | Session 3 – The patient perspective in health technology assessment |  |  | x | x | x |
| 16 | HAS | 1st annual webinar of public involvement for patients and consumers: The panorama of user involvement, Health product assessments |  | x |  | x |  |
| 17 | HAS | 2nd annual webinar of public involvement for patients and consumers- Facilitating your arrival to participate in the work of the HAS, Medicines, and health technologies: developments in health technology assessment and focus on early access |  |  |  | x | x |
| 18 | HITAP | Explains what HTA is, and roles of different stakeholders in the HTA process | x | x |  | x |  |
| 19 | HIQA | Guide to explain HTA at the HIQA: overview of HTA, HTA process, HTA content, outcomes of assessment, further information including references | x | x | x | x | x |
| 20 | HIQA | Provides guidelines for evaluating clinical effectiveness for health technologies in Ireland, definitions of key terms, measures of effect, methods of comparison, | x |  | x | x | x |
| 21 | HIQA | Provides an overview of what HTA is, economic guidelines including type of evaluation, cost perspectives, outcome perspectives, choice of comparator, synthesis of effectiveness, outcome measurement, discount rate, sensitivity analysis, equity rating | x |  | x | x | x |
| 22 | HTA-AU | Explains HTA for Australian Government subsidy, purpose of HTA, public involvement in HTA, | x | x | x |  | x |
| 23 | HTA-AU | Explains the Role of Consumer Engagement and Evidence, consumer HTA experiences | x | x | x | x | x |
| 24 | HTW | Guide to Patient/Carer Group Submissions: includes types of information to be included in the submission, methods to collect this information |  |  |  | x |  |
| 25 | HTW | Attending a Health Technology Wales Appraisal Panel meeting: key replies to questions asked about these appraisal meetings |  | x |  |  |  |
| 26 | HTW | Explains how Health Technology Wales (HTW) performs 'health technology assessments' to determine the potential value of health interventions and how patient groups can get involved in that process. | x | x | x | x | x |
| 27 | INESSS | Governance, methods of patient and citizen participation |  |  |  |  |  |
| 28 | IQWIG | Explains how patients can participate and requirements of such participation (report plans, preliminary reports, preliminary ThemenCheck reports, drafts of the General Methods) |  | x |  | x | x |
| 29 | KCE | Explains the different HTA processes, how patients can participate in the KCE's work, levels of engagement, type of patients involved, how they are identified, recruted and selected | x | x | x | x | x |
| 30 | NICE | Provides overview of the different forms of technology appraisal at the NICE, explains NHS constitutions, technology appraisal decisions, guidance overview, more information |  | x | x | x | x |
| 31 | NICE | Explains what technology appraisals are, scoping, how patient and carer organizations can get involved in scoping, the scoping consultation, the scoping workshop |  | x |  | x |  |
| 32 | NICE | Explains patient and public involvement in medicines appraisals at NICE, market access and HTA in England, role of committee, patient experts and what they provide | x | x |  | x | x |
| 33 | NICE | Explains public involvement medical technologies guidance, role of committee, levels of evidence in MedTech evaluation |  | x |  | x |  |
| 34 | NICE | Explains NICE Public Involvement Programme, in relation to Types of patient input for medical technology guidance |  | x |  |  |  |
| 35 | NICE | NICE lay member toolkit- covers who to ask, tips for preparing new role and first meeting, what happens after the meeting, preparing for all committee meetings, role during committee meetings, role in final stages of developing NICE guideline |  |  |  | x |  |
| 36 | NICE | Series of online modules- introduction to NICE, role and value, being an effective lay member, committees, how NICE uses evidence, equalities, introduction to health economics, working with networks | x | x | x | x | x |
| 37 | NICE | Covers communication tips during a virtual meeting |  |  |  |  |  |
| 38 | RedETS | Covers: Current framework of HTA in the Spanish national health system, Participation of patients and citizens in HTA, quantitative and qualitative research methods, health research, Practical aspects of patient and citizen participation for an effective HTA contribution | x | x | x | x | x |
| 39 | SHTG | Guide to Support Patient Organization Submissions including information required for a submission, how to collect this information |  |  |  | x |  |
| 40 | SMC | Guide for Patient Group Partners- covers the SMC process and planning and completing a submission, useful resources |  |  |  | x |  |
| 41 | SMC | HTA training- public involvement in HTA, submission form and guide, Patient and Clinical Engagement | x | x |  |  |  |
| 42 | SMC | Explains how SMC pharmacists assess a medicine- issues with clinical trials, importance of critical appraisal, assessment team. |  | x | x | x |  |
| **European and international patient and consumer groups** |
| 43 | Beacon UK | HTA course including description of the different UK HTA agencies and their respective HTA processes, patient involvement in HTA with the focus on rare diseases, glossary list | x | x | x | x | x |
| 44 | Beacon UK | Health economics understanding explains what HTA is, preparing patient group for HTA, |  | x | x | x | x |
| 45 | ECPC | Covers what is HTA, practical guide for patient contribution to HTA, getting involved in the regional/national level, references, glossary | x | x | x | x |  |
| 46 | ECPC | Understanding Health Technology Assessment covers Health economics, Involvement of Patient Organisations in the HTA Process, value of health, clinical trials, references | x | x | x | x | x |
| 47 | EUPATI | Glossary List |  |  |  |  |  |
| 48 | EUPATI | HTA course: introduction, bodies and principles, quantitative and qualitative evaluation methods, patient involvement in HTA | x | x | x | x | x |
| 49 | EURORDIS | Covers: Recommendations on the required capabilities for patient engagement, conflict of interest in patient engagement, market access and HTA | x | x | x | x | x |
| 50 | IAPO | Provides definition of what HTA is, a health technology, policy landmarks including Patients’ unique views can increase the quality ofdecision-making, Patients’ experiences can represent an invaluable sourceof data, What makes patients’ input truly unique? | x |  |  |  |  |
| 51 | IPPOSI | Principles and practices of Health Technology Assessment (HTA) –what a health technology is, what HTA is, and why it is becoming increasingly important within Europeanhealth systems, how patients can become involved with HTA | x | x | x | x | x |
| 52 | LE | Covers what Health Technology Assessment (HTA) is, why is patient involvement in HTA is important, at what point and how patients can get involved in HTA and what patients can contribute to the process. | x |  | x | x | x |
| 53 | MPE | Covers what HTA is, when does it take place, who conducts, information assessed, appraisal committees, criteria for HTA bodies in decision-making, how patient organizations can influence HTA decisions, references | x | x | x | x | x |
| 54 | MPE | Webinar on reimbursement and Health Technology Assessment (HTA) in Europe covering HTAi standards and values, why HTA needs patient involvement, patient input, examples of evidence, ethics, |  | x | x | x | x |
| 55 | PVI | Covers what patient-based evidence is, Patient preference research: what it is, how is it used, PROMS research, qualitative research in HTA |  |  |  | x | x |
| 56 | PVI | Explains how Australia's healthcare reimbursement system works and how patients and patient groups can get involved | x |  |  |  |  |
| 57 | PVI | Patient based evidence for PBAC and MSAC submissions covers why patient groups might want to get involved in research into patients' needs, preferences and experiences. |  |  |  | x |  |
| 58 | PVI | The patient voice and health economics, role of patient and consumer groups, how consumer input is taken into consideration | x |  | x | x | x |
| **Other Organizations** |
| 59 | ANSM | Consumer guide to the ANSM: missions, values, medicines cycle and procedures, medical device cycle and procedures, patient input in pharmacovigilance |  | x |  |  |  |
| 60 | ANSES | Biotechnologies: Risk assessment, technology assessment and responsible research and innovation, public engagement |  |  |  | x | x |
| 61 | EMA | Principles of HTA, evidence for HTA, example of NICE health technology appraisal | x | x | x | x | x |
| 62 | EUnetHTA | Explains the patient and social aspect domain which takes patients or individuals in whose care a healthtechnology is used as a point of reference in an HTA, why it is important, relation to other domains in the Core Model, screening and pharmaceutical specific content | x |  | x | x | x |
| 63 | EUnetHTA | Patient Input in Relative Effectiveness Assessments, definitions of patients and caregivers, patient input, confidentiality, methods for patient input |  |  |  |  |  |
| 64 | GIN | Delivers on tools and tips on how to support patient involvement in HTA- differences between patient input and patient evidence, highlights the international values and standards for HTAs, the lifecycle of patient input into HTAs and considering impact of this input, includes references | x | x |  |  |  |
| 65 | HTAi | Patient involvement in HTA, first book- demonstrates academic, policy, HTA practice and patient organization perspectives that are focused on HTADetails the policy foundation, case studies of current experience and methods to obtain patients' perspectives | x |  | x | x | x |
| 66 | HTAi | Explains what early HTA is in a simplified, animated format | x | x |  |  | x |
| 67 | HTAi | Introduction to Health Technology Assessment (HTA)- health care systems, what it is, how can patients can patients get involved, who will help patients get involved | x | x |  |  |  |
| 68 | HTAi | Provides an overview of the HTA process and how the submission will be used in the assessment of the medicine and to make recommendations, steps involved in completing a submission, methods to collect patient and caregiver input, summarizing and reporting responses | x |  |  |  |  |
| 69 | HTAi | Provides guidance for patient organizations on the Summary of Information for Patients template explaining the 4 sections: submission summary, current landscape, the medicine, further information, glossary, and references |  |  |  |  |  |
| 70 | HTAi | Ethical considerations for patient groups collecting and reporting information for HTA submissions |  |  |  |  |  |
| 71 | HTAi | Good Practice Examples of Patient and Public Involvementin Health Technology Assessment - contains examples of the way in which HTA agencies involve patients and the public inHTA. |  |  |  |  |  |
| 72 | HTAi | Provides the values and quality standards for patient involvement in HTA including the general and individual HTA processes |  |  |  |  |  |
| 73 | HTAi | HTAi Glossary |  |  |  |  |  |
| 74 | HTAi | HTAi Patient Preferences Webinar Series:understand the role of patient preferences in HTA reviews, Designing Patient Preference Studies for HTA, Patient Preferences Research in HTA Decision-Making, Patient Preferences and Values Studies in Oncology and Rare Diseases |  |  |  |  |  |
| 75 | HTAi | Presentation of the assessment of the current landscape of HTA use of patient preferences in HTA decision-making, including role of PPI in HTA | x |  |  |  |  |
| 76 | INAHTA | Presentation of patient involvement experiences of two HTA agencies who have used the PCIG resources | x |  |  |  |  |
| 77 | INAHTA | Position statement on patient involvement- who, what, when, why, references |  |  |  |  |  |
| 78 | ISPOR | HTA training program, introduction to HTA- covers what is HTA, why is it important, what are the best practices, current and future issues, implementing HTA, local considerations, framing and scoping in HTA | x | x | x | x | x |
| 79 | NIHR | Covers knowledge of the NIHR and Patient and Public Involvement (PPI), public reviewing roles and useful skills, how to review research documents from a patient and public point of view |  |  |  |  |  |
| 80 | NLM-NICHSR | Origins of technology assessment, early health technology assessment, fundamental concepts, and definitions, basic HTA frameworks, references, glossary | x | x | x | x | x |
| 81 | PARADIGM | Early dialogues in HTA: rationale for engaging patients in Early Dialogues |  |  |  | x | x |
| 82 | WHO | Provides key definition of HTA, references | x |  |  |  |  |

**Table 3. Selected training tools classified according to key PPI in HTA themes.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Source** | **Content description** | **1.    How does a patient and/or consumer contribute to HTA?** | **2. How are patient and consumer views considered by the HTA body for technology assessment?** | **3. The HTA body’s governance and the role of the PPI department within body** | **4. What can HTA bodies expect from an HTA patient/ consumer contribution?** | **5.Confidentiality and ethical practices, standards, and/or values** | **6. References and other resources (e.g., glossary),** | **7.Soft skills (e.g., communication).** |
| **HTA bodies (including REDETS which is a network of Spanish HTA bodies)** |
| 1 | ACE | Explains what HTA is and ACE's processes and methods |   |   |   |   |   |   |   |
| 2 | ACE | Explains what HTA is and ACE's processes and methods |   |   |   |   |   |   |   |
| 3 | ACE | Glossary List |   |   |   |   |   | x |   |
| 4 | CADTH | Explains patient and community engagement, participation methods, PI in their organizational government, common acronyms | x | x | x | x | x | x |   |
| 5 | CADTH | Covering a variety of topics including HTA, process and methods, patient engagement, patient perspectives etc. | x | x | x | x | x | x | x |
| 6 | CADTH | Explains the process of CADTH Drug Reimbursement Reviews | x | x |   |   | x |   |   |
| 7 | CDE | Explains the decision-making process for medicines reimbursement under the national health insurance and role of CDE and other actors |   |   |   |   |   |   |   |
| 8 | G-BA | Covers HTA, methods and governance, coordination meetings (e.g., EU HTA) | x |   |   |   | x | x |   |
| 9 | G-BA | Soft skills training including presentation, speaking, virtual meeting communications |   |   |   |   |   |   | x |
| 10 | HAS | Guidelines on how to contribute to a patient submission for a medicine assessment (reimbursement and early access), patient submission template | x | x | x | x |   |   |   |
| 11 | HAS | Guidelines on how to submit a patient organization submission for a medical device, patient organization submission template | x | x | x | x |   |   |   |
| 12 | HAS (+ANSM) | Early access medicines: process and practical arrangements, data collection, consumer participation; role of ANSM and benefit/risk assessment; HAS doctrine and criteria assessment arrangements. | x | x |   | x |   |   |   |
| 13 | HAS | Online patient and consumer guide to early access medicines: medicines concerned, access conditions, role of patient and consumer organizations, | x |   |   | x | x |   |   |
| 14 | HAS | Medicines devices assessment:Information Day for patient organizations covering topics such as HAS and patient organizations, commissions and patient organizations, patient organization submissions | x | x |   | x |   |   |   |
| 15 | HAS | Session 3 – The patient perspective in health technology assessment | x | x |   | x |   |   |   |
| 16 | HAS | 1st annual webinar of public involvement for patients and consumers: The panorama of user involvement, Health product assessments | x | x | x | x |   |   |   |
| 17 | HAS | 2nd annual webinar of public involvement for patients and consumers- Facilitating your arrival to participate in the work of the HAS, Medicines, and health technologies: developments in health technology assessment and focus on early access | x | x | x | x |   |   |   |
| 18 | HITAP | Explains what HTA is, and roles of different stakeholders in the HTA process | x |   |   |   |   |   |   |
| 19 | HIQA | Guide to explain HTA at the HIQA: overview of HTA, HTA process, HTA content, outcomes of assessment, further information including references | x | x |   | x | x | x |   |
| 20 | HIQA | Provides guidelines for evaluating clinical effectiveness for health technologies in Ireland, definitions of key terms, measures of effect, methods of comparison, |   | x |   |   |   | x |   |
| 21 | HIQA | Provides an overview of what HTA is, economic guidelines including type of evaluation, cost perspectives, outcome perspectives, choice of comparator, synthesis of effectiveness, outcome measurement, discount rate, sensitivity analysis, equity rating | x | x |   |   |   | x |   |
| 22 | HTA-AU | Explains HTA for Australian Government subsidy, purpose of HTA, public involvement in HTA, |   |   | x |   | x |   |   |
| 23 | HTA-AU | Explains the Role of Consumer Engagement and Evidence, consumer HTA experiences | x | x | x | x | x | x |   |
| 24 | HTW | Guide to Patient/Carer Group Submissions: includes types of information to be included in the submission, methods to collect this information | x | x | x | x | x | x | x |
| 25 | HTW | Attending a Health Technology Wales Appraisal Panel meeting: key replies to questions asked about these appraisal meetings | x |   |   | x | x | x | x |
| 26 | HTW | Explains how Health Technology Wales (HTW) performs 'health technology assessments' to determine the potential value of health interventions and how patient groups can get involved in that process. | x | x | x | x | x | x | x |
| 27 | INESSS | Governance, methods of patient and citizen participation | x | x | x | x | x |   |   |
| 28 | IQWIG | Explains how patients can participate and requirements of such participation (report plans, preliminary reports, preliminary ThemenCheck reports, drafts of the General Methods) | x | x |   | x |   |   |   |
| 29 | KCE | Explains the different HTA processes, how patients can participate in the KCE's work, levels of engagement, type of patients involved, how they are identified, recruted and selected | x | x | x | x |   |   | x |
| 30 | NICE | Provides overview of the different forms of technology appraisal at the NICE, explains NHS constitutions, technology appraisal decisions, guidance overview, more information | x | x |   | x |   |   |   |
| 31 | NICE | Explains what technology appraisals are, scoping, how patient and carer organizations can get involved in scoping, the scoping consultation, the scoping workshop | x | x | x | x |   |   |   |
| 32 | NICE | Explains patient and public involvement in medicines appraisals at NICE, market access and HTA in England, role of committee, patient experts and what they provide | x | x | x | x |   |   |   |
| 33 | NICE | Explains public involvement medical technologies guidance, role of committee, levels of evidence in MedTech evaluation | x | x | x | x |   |   |   |
| 34 | NICE | Explains NICE Public Involvement Programme, in relation to Types of patient input for medical technology guidance | x | x | x | x |   |   |   |
| 35 | NICE | NICE lay member toolkit- covers who to ask, tips for preparing new role and first meeting, what happens after the meeting, preparing for all committee meetings, role during committee meetings, role in final stages of developing NICE guideline | x | x |   | x | x | x | x |
| 36 | NICE | Series of online modules- introduction to NICE, role and value, being an effective lay member, committees, how NICE uses evidence, equalities, introduction to health economics, working with networks | x | x | x | x | x | x | x |
| 37 | NICE | Covers communication tips during a virtual meeting |   |   |   |   |   | x | x |
| 38 | RedETS | Covers: Current framework of HTA in the Spanish national health system, Participation of patients and citizens in HTA, quantitative and qualitative research methods, health research, Practical aspects of patient and citizen participation for an effective HTA contribution | x | x | x | x | x | x |   |
| 39 | SHTG | Guide to Support Patient Organization Submissions including information required for a submission, how to collect this information | x |   |   | x |   |   |   |
| 40 | SMC | Guide for Patient Group Partners- covers the SMC process and planning and completing a submission, useful resources | x | x | x | x |   | x |   |
| 41 | SMC | HTA training- public involvement in HTA, submission form and guide, Patient and Clinical Engagement | x | x | x | x |   |   |   |
| 42 | SMC | Explains how SMC pharmacists assess a medicine- issues with clinical trials, importance of critical appraisal, assessment team. |   |   |   |   |   | x |   |
| **European and International Patient Groups** |
| 43 | Beacon UK | HTA course including description of the different UK HTA agencies and their respective HTA processes, patient involvement in HTA with the focus on rare diseases, glossary list | x | x | x | x | x | x |   |
| 44 | Beacon UK | Health economics understanding explains what HTA is, preparing patient group for HTA, | x | x |   | x |   |   |   |
| 45 | ECPC | Covers what is HTA, practical guide for patient contribution to HTA, getting involved in the regional/national level, references, glossary | x | x | x | x | x | x |   |
| 46 | ECPC | Understanding Health Technology Assessment covers Health economics, Involvement of Patient Organisations in the HTA Process, value of health, clinical trials, references | x | x | x | x |   | x |   |
| 47 | EUPATI | Glossary List |   |   |   |   |   | x |   |
| 48 | EUPATI | HTA course: introduction, bodies and principles, quantitative and qualitative evaluation methods, patient involvement in HTA | x | x | x | x | x | x |   |
| 49 | EURORDIS | Covers: Recommendations on the required capabilities for patient engagement, conflict of interest in patient engagement, market access and HTA |   | x |   | x | x | x |   |
| 50 | IAPO | Provides definition of what HTA is, a health technology, policy landmarks including Patients’ unique views can increase the quality ofdecision-making, Patients’ experiences can represent an invaluable sourceof data, What makes patients’ input truly unique? |   | x |   | x |   | x |   |
| 51 | IPPOSI | Principles and practices of Health Technology Assessment (HTA) –what a health technology is, what HTA is, and why it is becoming increasingly important within Europeanhealth systems, how patients can become involved with HTA | x | x | x | x | x | x | x |
| 52 | LE | Covers what Health Technology Assessment (HTA) is, why is patient involvement in HTA is important, at what point and how patients can get involved in HTA and what patients can contribute to the process. | x | x |   | x |   | x |   |
| 53 | MPE | Covers what HTA is, when does it take place, who conducts, information assessed, appraisal committees, criteria for HTA bodies in decision-making, how patient organizations can influence HTA decisions, references | x | x |   | x | x | x |   |
| 54 | MPE | Webinar on reimbursement and Health Technology Assessment (HTA) in Europe covering HTAi standards and values, why HTA needs patient involvement, patient input, examples of evidence, ethics, | x | x | x | x | x | x | x |
| 55 | PVI | Covers what patient-based evidence is, Patient preference research: what it is, how is it used, PROMS research, qualitative research in HTA |   |   |   |   |   |   |   |
| 56 | PVI | Explains how Australia's healthcare reimbursement system works and how patients and patient groups can get involved | x | x |   | x |   |   |   |
| 57 | PVI | Patient based evidence for PBAC and MSAC submissions covers why patient groups might want to get involved in research into patients' needs, preferences and experiences. | x | x |   | x |   |   |   |
| 58 | PVI | The patient voice and health economics, role of patient and consumer groups, how consumer input is taken into consideration | x | x | x | x |   |   |   |
| **Other Organizations** |
| 59 | ANSM | Consumer guide to the ANSM: missions, values, medicines cycle and procedures, medical device cycle and procedures, patient input in pharmacovigilance |   |   |   |   | x | x |   |
| 60 | ANSES | Biotechnologies: Risk assessment, technology assessment and responsible research and innovation, public engagement | x | x |   |   |   |   |   |
| 61 | EMA | Principles of HTA, evidence for HTA, example of NICE health technology appraisal | x |   |   |   |   |   |   |
| 62 | EUnetHTA | Explains the patient and social aspect domain which takes patients or individuals in whose care a healthtechnology is used as a point of reference in an HTA, why it is important, relation to other domains in the Core Model, screening and pharmaceutical specific content | x | x |   | x | x | x |   |
| 63 | EUnetHTA | Patient Input in Relative Effectiveness Assessments, definitions of patients and caregivers, patient input, confidentiality, methods for patient input | x | x |   | x | x | x |   |
| 64 | GIN | Delivers on tools and tips on how to support patient involvement in HTA- differences between patient input and patient evidence, highlights the international values and standards for HTAs, the lifecycle of patient input into HTAs and considering impact of this input, includes references | x | x |   | x | x | x |   |
| 65 | HTAi | Patient involvement in HTA, first book- demonstrates academic, policy, HTA practice and patient organization perspectives that are focused on HTADetails the policy foundation, case studies of current experience and methods to obtain patients' perspectives | x | x |   | x | x | x |   |
| 66 | HTAi | Explains what early HTA is in a simplified, animated format | x |   |   |   |   |   |   |
| 67 | HTAi | Introduction to Health Technology Assessment (HTA)- health care systems, what it is, how can patients can patients get involved, who will help patients get involved | x | x |   | x |   | x |   |
| 68 | HTAi | Provides an overview of the HTA process and how the submission will be used in the assessment of the medicine and to make recommendations, steps involved in completing a submission, methods to collect patient and caregiver input, summarizing and reporting responses | x | x |   | x | x |   |   |
| 69 | HTAi | Provides guidance for patient organizations on the Summary of Information for Patients template explaining the 4 sections: submission summary, current landscape, the medicine, further information, glossary, and references | x | x |   | x |   |   |   |
| 70 | HTAi | Ethical considerations for patient groups collecting and reporting information for HTA submissions |   | x |   |   | x | x |   |
| 71 | HTAi | Good Practice Examples of Patient and Public Involvementin Health Technology Assessment - contains examples of the way in which HTA agencies involve patients and the public inHTA. | x | x | x | x | x | x |   |
| 72 | HTAi | Provides the values and quality standards for patient involvement in HTA including the general and individual HTA processes | x | x |   | x | x | x |   |
| 73 | HTAi | HTAi Glossary | x | x |   | x | x | x |   |
| 74 | HTAi | HTAi Patient Preferences Webinar Series:understand the role of patient preferences in HTA reviews, Designing Patient Preference Studies for HTA, Patient Preferences Research in HTA Decision-Making, Patient Preferences and Values Studies in Oncology and Rare Diseases | x | x |   | x |   | x |   |
| 75 | HTAi | Presentation of the assessment of the current landscape of HTA use of patient preferences in HTA decision-making, including role of PPI in HTA |   |   |   |   |   | x |   |
| 76 | INAHTA | Presentation of patient involvement experiences of two HTA agencies who have used the PCIG resources | x | x |   | x |   | x |   |
| 77 | INAHTA | Position statement on patient involvement- who, what, when, why, references | x | x |   | x |   | x |   |
| 78 | ISPOR | HTA training program, introduction to HTA- covers what is HTA, why is it important, what are the best practices, current and future issues, implementing HTA, local considerations, framing and scoping in HTA | x | x |   | x | x | x |   |
| 79 | NIHR | Covers knowledge of the NIHR and Patient and Public Involvement (PPI), public reviewing roles and useful skills, how to review research documents from a patient and public point of view |   |   |   |   | x | x | x |
| 80 | NLM-NICHSR | Origins of technology assessment, early health technology assessment, fundamental concepts, and definitions, basic HTA frameworks, references, glossary | x | x |   | x | x | x |   |
| 81 | PARADIGM | Early dialogues in HTA: rationale for engaging patients in Early Dialogues | x | x | x | x | x | x |   |
| 82 | WHO | Provides key definition of HTA, references |   |   |   |   |   | x |   |

**Source codes:**

***Bodies involved in HTA***

* Agency for Care Effectiveness (ACE),
* Belgian Health Care Knowledge Centre (KCE),
* Canadian Agency for Drugs and Technologies in Health (CADTH),
* Center for Drug Evaluation (CDE),
* Gemeinsamer Bundesausschuss (G-BA),
* Haute Autorité de santé (HAS)
* Health Information and Quality Authority (HIQA),
* Health Intervention and Technology Assessment Program, Ministry of Health (HITAP),
* Health Technology Wales (HTW),
* HTA Consumer Evidence and Engagement Unit, Department of Health, Australia (HTA-AU),
* National Institute of Care Excellence (NICE),
* Institute for Quality and Efficiency in Health Care (IQWIG),
* Institut national d’excellence en santé et en services sociaux (INESSS),
* Scottish Health Technologies Group (SHTG),
* Scottish Medicines Consortium, Healthcare Improvement Scotland (SMC),
* Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del Sistema Nacional de Salud (RedETS).

***European and international patient and consumer groups***

* Beacon UK (Beacon),
* European Cancer Patient Coalition (ECPC),
* European Organization for Rare Diseases (EURORDIS),
* European Patients' Academy on Therapeutic Innovation (EUPATI),
* International Alliance of Patient Organizations (IAPO),
* Irish Platform for Patient Organizations, Science, and Industry (IPPOSI),
* Lupus Europe (LE),
* Myeloma Patients Europe (MPE),
* Patient Voice Initiative (PVI).

***Other organizations***

* Agence Nationale de sécurité du médicament et des produits de santé (ANSM),
* Agence Nationale Sécurité Sanitaire Alimentaire Nationale (ANSES),
* European Medicines Agency (EMA),
* European Network for HTA (EUnetHTA),
* Guidelines International Network (GIN),
* Health Technology Assessment International (HTAI),
* International Network of Agencies for Health Technology Assessment (INAHTA),
* International Society for Pharmacoeconomics and Outcomes Research (ISPOR),
* National Institute of Health and Care Research (NIHR),
* National Library of Medicine: National Information Center on Health Services Research and Health Care Technology (NLM-NICHSR)
* National Health Council, (NHC),
* Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM),
* World Health Organization (WHO).